Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses
- 1 November 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 11 (11) , 1135-1145
Abstract
Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus.Keywords
This publication has 69 references indexed in Scilit:
- Surveillance and Vaccine Effectiveness of an Influenza Epidemic Predominated by Vaccine-Mismatched Influenza B/Yamagata-Lineage Viruses in Taiwan, 2011−12 SeasonPLOS ONE, 2013
- Recovery of Influenza B Virus with the H273Y Point Mutation in the Neuraminidase Active Site from a Human PatientJournal of Clinical Microbiology, 2012
- Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance PerspectiveViruses, 2010
- Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2010
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational LevelJournal of Biological Chemistry, 2009
- CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus ActivityAntimicrobial Agents and Chemotherapy, 2009
- Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008Antimicrobial Agents and Chemotherapy, 2008
- The Evolutionary Dynamics of Human Influenza B VirusJournal of Molecular Evolution, 2008
- Influenza C Virus Infection in Children, SpainEmerging Infectious Diseases, 2006
- Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2006